The Hemodynamic Response to Prolonged Dobutamine Infusion
A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.
Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.
|Study Design:||Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
- Heart rate [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]
- Systolic blood pressure [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||December 2019|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
3 hours infusion of dobutamine
Drug: 3 hours intravenous dobutamine
Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01042873
|Hadassah University Hospital||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Mordechai Muszkat, MD 972-2-6777335 email@example.com|
|Principal Investigator: Mordechai Muszkat, MD|